Drug intelligence / Profile preview

paracetamol + ketorolac + granisetron

Development stage
Unknown
Lead developer
Ain Shams University
Modality
Small Molecules
Administration
Intravenous
01

Overview

This combination is a multi-modal analgesic and antiemetic regimen consisting of paracetamol (acetaminophen), ketorolac, and granisetron. It is primarily used for perioperative pain management and the prevention of postoperative nausea and vomiting (PONV). Paracetamol and ketorolac provide synergistic non-opioid analgesia by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of pro-inflammatory prostaglandins. Granisetron is a selective 5-HT3 receptor antagonist that blocks serotonin-mediated emetic signals in the central and peripheral nervous systems. This specific regimen was utilized as a standardized baseline analgesia protocol in clinical research conducted by Ain Shams University, particularly in studies evaluating the efficacy of regional anesthesia techniques like the Serratus Posterior Superior Intercostal Plane Block (SPSIPB) for breast cancer surgery.

Other names
paracetamol + ketorolac + granisetronAnalgesia mangement group A,BAcetaminophen + Ketorolac + Granisetron
02

Targets

HTR3A (5-hydroxytryptamine receptor 3A)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on paracetamol + ketorolac + granisetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + ketorolac + granisetron.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call